Serial Magnetic Resonance Imaging in Active Surveillance of Prostate Cancer: Incremental Value

Abstract

Purpose We assessed whether changes in serial multiparametric magnetic resonance imaging can help predict the pathological progression of prostate cancer in men on active surveillance. Materials and Methods A retrospective cohort study was conducted of 49 consecutive men with Gleason 6 prostate cancer who underwent multi-parametric magnetic resonance imaging at baseline and again more than 6 months later, each followed by a targeted prostate biopsy, between January 2011 and May 2015. We evaluated whether progression on multiparametric magnetic resonance imaging (an increase in index lesion suspicion score, increase in index lesion volume or decrease in index lesion apparent diffusion coefficient) could predict pathological progression (Gleason 3 + 4 or greater on subsequent biopsy, in systematic or targeted cores). Diagnostic performance of multiparametric magnetic resonance imaging was determined with and without clinical data using a binary logistic regression model. Results The mean interval between baseline and followup multiparametric magnetic resonance imaging was 28.3 months (range 11 to 43). Pathological progression occurred in 19 patients (39%). The sensitivity, specificity, positive predictive value and negative predictive value of multiparametric magnetic resonance imaging was 37%, 90%, 69% and 70%, respectively. Area under the receiver operating characteristic curve was 0.63. A logistic regression model using clinical information (maximum cancer core length greater than 3 mm on baseline biopsy or a prostate specific antigen density greater than 0.15 ng/ml2 at followup biopsy) had an AUC of 0.87 for predicting pathological progression. The addition of serial multiparametric magnetic resonance imaging data significantly improved the AUC to 0.91 (p = 0.044). Conclusions Serial multiparametric magnetic resonance imaging adds incremental value to prostate specific antigen density and baseline cancer core length for predicting Gleason 6 upgrading in men on active surveillance.

Risk Stratification Among Men With Prostate Imaging Reporting and Data System version 2 Category 3 Transition Zone Lesions: Is Biopsy Always Necessary?

“…The reference standard in all cases was FB, which included systematic biopsy of 12 sites and additional targeted biopsy of each suspicious lesion identified on MRI, as described previously [11]. FB was performed by a single board-certified urologist with experience of approximately 1000 FBs at the onset of the study period [12].…”

When no treatment is the best treatment: Active surveillance strategies for low risk prostate cancers

“…Although experience in this area is limited, converging evidence from MRI-based AS cohorts suggests that serial imaging improves the prediction of pathological progression compared to clinicopathological variables alone, whereas stable MRI findings are associated with pathological stability [46,47,48]. A meta-analysis of MRI performance involving a total of 1028 surveillance patients demonstrated a low positive predictive value and sensitivity but a high negative predictive value and specificity, suggesting that although a negative MRI is reassuring, men with suspicious MRI lesions should be closely monitored [49].…”

Active Surveillance of Prostate Cancer: Use, Outcomes, Imaging, and Diagnostic Tools

“…Upgrading to Gleason score 3+4=7 was documented for 17 men (29%), and the positive and negative predictive values of mpMRI for Gleason score progression were 53% (95% CI, 28%-77%) and 80% (95% CI, 65%-91%), respectively. One recent retrospective study by Felker et al 65 included 49 consecutive men with Gleason score 6 prostate cancer who underwent mpMRI and targeted prostate biopsy at baseline and again more than 6 months later. Over a mean follow-up of 28.3 months (range, 11-43 months), Gleason score progression occurred for 19 patients (39%).…”